Free Trial
NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

Innate Pharma logo
$2.02 +0.01 (+0.55%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Innate Pharma Stock (NASDAQ:IPHA)

Advanced

Key Stats

Today's Range
$2.04
$2.10
50-Day Range
$1.78
$2.28
52-Week Range
$1.29
$3.51
Volume
13,786 shs
Average Volume
21,789 shs
Market Capitalization
$189.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Hold

Company Overview

Innate Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

IPHA MarketRank™: 

Innate Pharma scored higher than 54% of companies evaluated by MarketBeat, and ranked 530th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innate Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Innate Pharma has a consensus price target of $6.50, representing about 215.5% upside from its current price of $2.06.

  • Amount of Analyst Coverage

    Innate Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Innate Pharma's stock forecast and price target.
  • Price to Book Value per Share Ratio

    Innate Pharma has a P/B Ratio of 18.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.05% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.05% of the outstanding shares of Innate Pharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    4 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innate Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.16% of the stock of Innate Pharma is held by institutions.

  • Read more about Innate Pharma's insider trading history.
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IPHA Stock News Headlines

Innate Pharma management to meet with BTIG
Brokers Offer Predictions for Innate Pharma FY2025 Earnings
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Earnings Scheduled For September 17, 2025
See More Headlines

IPHA Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $1.84 at the beginning of the year. Since then, IPHA stock has increased by 12.0% and is now trading at $2.06.

Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Pfizer (PFE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Altimmune (ALT), Cidara Therapeutics (CDTX) and Fulcrum Therapeutics (FULC).

Company Calendar

Today
10/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IPHA
CIK
1598599
Fax
N/A
Employees
220
Year Founded
1999

Price Target and Rating

High Price Target
$11.00
Low Price Target
$2.00
Potential Upside/Downside
+215.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
3.52
Current Ratio
2.21
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$21.77 million
Price / Sales
8.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.11 per share
Price / Book
18.73

Miscellaneous

Outstanding Shares
92,180,000
Free Float
62,787,000
Market Cap
$189.89 million
Optionable
Not Optionable
Beta
0.04

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IPHA) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners